W. Rathmell
Last active: 10/30/2019

Profile

Our research program is focused on the basic mechanisms, translational aspects, and clinical attributes of the renal cell carcinomas.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The Immune Landscape of Cancer. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I (2019) Immunity 51(2): 411-412
    › Primary publication · 31433971 (PubMed)
  2. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI (2019) Lancet Oncol 20(10): 1386-1394
    › Primary publication · 31427205 (PubMed)
  3. Empowering ASCI's support of physician-scientists through stronger institutional connections. Marr KA, Rathmell WK, Hawley JB, Guth KD (2019) J Clin Invest 129(4): 1516-1518
    › Primary publication · 30932915 (PubMed) · PMC6436849 (PubMed Central)
  4. loss sensitizes cells to PI3Kβ and AKT inhibition. Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK (2019) Oncotarget 10(6): 647-659
    › Primary publication · 30774762 (PubMed) · PMC6363018 (PubMed Central)
  5. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. Chappell JC, Payne LB, Rathmell WK (2019) J Clin Invest 129(2): 442-451
    › Primary publication · 30614813 (PubMed) · PMC6355237 (PubMed Central)
  6. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC (2018) Cell 175(7): 1780-1795.e19
    › Primary publication · 30392958 (PubMed) · PMC6361668 (PubMed Central)
  7. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang H (2018) Cell Rep 25(5): 1304-1317.e5
    › Primary publication · 30380420 (PubMed) · PMC6326181 (PubMed Central)
  8. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. Rathmell WK, Rathmell JC, Linehan WM (2018) J Clin Oncol : JCO2018792309
    › Primary publication · 30372395 (PubMed) · PMC6488445 (PubMed Central)
  9. A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. Nakajima E, Leger P, Mayer IA, Neuss MN, Chism DD, Rathmell WK (2017) Kidney Cancer 1(1): 83-88
    › Primary publication · 30334008 (PubMed) · PMC6179105 (PubMed Central)
  10. Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). Ghatalia P, Rathmell WK (2018) Kidney Cancer 2(1): 23-29
    › Primary publication · 30320241 (PubMed) · PMC6176730 (PubMed Central)
  11. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T (2018) Nat Med 24(12): 1941
    › Primary publication · 30291359 (PubMed)
  12. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM (2019) Clin Genitourin Cancer 17(1): 1-6
    › Primary publication · 30287223 (PubMed) · PMC6348017 (PubMed Central)
  13. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R (2018) Cell Syst 7(4): 422-437.e7
    › Primary publication · 30268436 (PubMed) · PMC6370347 (PubMed Central)
  14. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) JAMA Oncol 4(12): 1721-1728
    › Primary publication · 30242316 (PubMed) · PMC6440712 (PubMed Central)
  15. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG (2018) J Clin Invest 128(11): 4804-4820
    › Primary publication · 30137025 (PubMed) · PMC6205406 (PubMed Central)
  16. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, Ganesan S, Bhanot G, Rathmell WK (2018) JCI Insight 3(16)
    › Primary publication · 30135306 (PubMed) · PMC6141170 (PubMed Central)
  17. Comprehensive Characterization of Cancer Driver Genes and Mutations. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group, Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L (2018) Cell 174(4): 1034-1035
    › Primary publication · 30096302 (PubMed)
  18. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Cancer Genome Atlas Research Network, Rätsch G (2018) Cancer Cell 34(2): 211-224.e6
    › Primary publication · 30078747 (PubMed)
  19. Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma. Rojas JD, Papadopoulou V, Czernuszewicz TJ, Rajamahendiran RM, Chytil A, Chiang YC, Chong DC, Bautch VL, Rathmell WK, Aylward S, Gessner RC, Dayton PA (2019) IEEE Trans Biomed Eng 66(3): 873-880
    › Primary publication · 30059292 (PubMed) · PMC6691901 (PubMed Central)
  20. Epigenetic modifiers: activities in renal cell carcinoma. de Cubas AA, Rathmell WK (2018) Nat Rev Urol 15(10): 599-614
    › Primary publication · 30030490 (PubMed)
  21. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG, Baldwin AS, Zhang Q (2018) Science 361(6399): 290-295
    › Primary publication · 30026228 (PubMed) · PMC6154478 (PubMed Central)
  22. Balancing dual demands on the physician-scientist workforce. Martin DM, Rathmell WK, Tavazoie SF (2018) J Clin Invest 128(8): 3204-3205
    › Primary publication · 30010627 (PubMed) · PMC6063500 (PubMed Central)
  23. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM (2018) Cell Rep 23(12): 3698
    › Primary publication · 29925010 (PubMed)
  24. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM, Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA (2018) Cell Rep 23(11): 3392-3406
    › Primary publication · 29898407 (PubMed) · PMC6075738 (PubMed Central)
  25. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T (2018) Nat Med 24(6): 749-757
    › Primary publication · 29867230 (PubMed) · PMC6721896 (PubMed Central)
  26. Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. Yin Q, Hung SC, Rathmell WK, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D (2018) Clin Radiol 73(9): 782-791
    › Primary publication · 29801658 (PubMed) · PMC6078810 (PubMed Central)
  27. Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YS, de Cubas AA, Khan A, Davis IJ, Strahl BD, Parker JS, Dere R, Walker CL, Rathmell WK (2018) Cancer Res 78(12): 3135-3146
    › Primary publication · 29724720 (PubMed) · PMC6004258 (PubMed Central)
  28. High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE (2018) Am J Pathol 188(7): 1510-1516
    › Primary publication · 29684361 (PubMed) · PMC6024179 (PubMed Central)
  29. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI (2018) J Clin Oncol 36(16): 1588-1593
    › Primary publication · 29641297 (PubMed)
  30. The Immune Landscape of Cancer. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I (2018) Immunity 48(4): 812-830.e14
    › Primary publication · 29628290 (PubMed) · PMC5982584 (PubMed Central)
  31. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Cancer Genome Atlas Research Network, Hu H (2018) Cell 173(2): 400-416.e11
    › Primary publication · 29625055 (PubMed) · PMC6066282 (PubMed Central)
  32. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Cancer Genome Atlas Research Network, Liang H (2018) Cell 173(2): 386-399.e12
    › Primary publication · 29625054 (PubMed) · PMC5890960 (PubMed Central)
  33. Comprehensive Characterization of Cancer Driver Genes and Mutations. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group, Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L (2018) Cell 173(2): 371-385.e18
    › Primary publication · 29625053 (PubMed) · PMC6029450 (PubMed Central)
  34. Pathogenic Germline Variants in 10,389 Adult Cancers. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L (2018) Cell 173(2): 355-370.e14
    › Primary publication · 29625052 (PubMed) · PMC5949147 (PubMed Central)
  35. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Cancer Genome Atlas Research Network, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M (2018) Cell 173(2): 338-354.e15
    › Primary publication · 29625051 (PubMed) · PMC5902191 (PubMed Central)
  36. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N (2018) Cell 173(2): 321-337.e10
    › Primary publication · 29625050 (PubMed) · PMC6070353 (PubMed Central)
  37. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G, Cancer Genome Atlas Research Network (2018) Cell 173(2): 305-320.e10
    › Primary publication · 29625049 (PubMed) · PMC5916814 (PubMed Central)
  38. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW (2018) Cell 173(2): 291-304.e6
    › Primary publication · 29625048 (PubMed) · PMC5957518 (PubMed Central)
  39. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, Cancer Genome Atlas Research Network, Thorsson V, Bass AJ, Laird PW (2018) Cancer Cell 33(4): 721-735.e8
    › Primary publication · 29622466 (PubMed) · PMC5966039 (PubMed Central)
  40. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Cancer Genome Atlas Research Network, Xie W, Yang D (2018) Cancer Cell 33(4): 706-720.e9
    › Primary publication · 29622465 (PubMed) · PMC6143179 (PubMed Central)
  41. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R (2018) Cancer Cell 33(4): 690-705.e9
    › Primary publication · 29622464 (PubMed) · PMC5959730 (PubMed Central)
  42. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M (2018) Cancer Cell 33(4): 676-689.e3
    › Primary publication · 29622463 (PubMed) · PMC6028190 (PubMed Central)
  43. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM (2018) Cell Rep 23(1): 313-326.e5
    › Primary publication · 29617669 (PubMed) · PMC6075733 (PubMed Central)
  44. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin P (2018) Cell Rep 23(1): 297-312.e12
    › Primary publication · 29617668 (PubMed) · PMC5906131 (PubMed Central)
  45. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Cancer Genome Atlas Research Network, Buonamici S, Yu L (2018) Cell Rep 23(1): 282-296.e4
    › Primary publication · 29617667 (PubMed) · PMC5933844 (PubMed Central)
  46. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ, Cancer Genome Atlas Research Network, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L (2018) Cell Rep 23(1): 270-281.e3
    › Primary publication · 29617666 (PubMed) · PMC6055527 (PubMed Central)
  47. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, Cancer Genome Atlas Research Network, Bathe OF, Liang H (2018) Cell Rep 23(1): 255-269.e4
    › Primary publication · 29617665 (PubMed) · PMC5916795 (PubMed Central)
  48. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Cancer Genome Atlas Research Network, Monnat RJ, Xiao Y, Wang C (2018) Cell Rep 23(1): 239-254.e6
    › Primary publication · 29617664 (PubMed) · PMC5961503 (PubMed Central)
  49. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Fusion Analysis Working Group, Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L (2018) Cell Rep 23(1): 227-238.e3
    › Primary publication · 29617662 (PubMed) · PMC5916809 (PubMed Central)
  50. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H (2018) Cell Rep 23(1): 213-226.e3
    › Primary publication · 29617661 (PubMed) · PMC5916807 (PubMed Central)
  51. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C (2018) Cell Rep 23(1): 194-212.e6
    › Primary publication · 29617660 (PubMed) · PMC6002769 (PubMed Central)
  52. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V (2018) Cell Rep 23(1): 181-193.e7
    › Primary publication · 29617659 (PubMed) · PMC5943714 (PubMed Central)
  53. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Cancer Genome Atlas Research Network, Sanchez Y, Greene CS (2018) Cell Rep 23(1): 172-180.e3
    › Primary publication · 29617658 (PubMed) · PMC5918694 (PubMed Central)
  54. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, Cancer Genome Atlas Network (2018) Cell Syst 6(3): 282-300.e2
    › Primary publication · 29596783 (PubMed) · PMC5892207 (PubMed Central)
  55. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L, MC3 Working Group, Cancer Genome Atlas Research Network (2018) Cell Syst 6(3): 271-281.e7
    › Primary publication · 29596782 (PubMed) · PMC6075717 (PubMed Central)
  56. Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. Arreola A, Payne LB, Julian MH, de Cubas AA, Daniels AB, Taylor S, Zhao H, Darden J, Bautch VL, Rathmell WK, Chappell JC (2018) JCI Insight 3(4)
    › Primary publication · 29467323 (PubMed) · PMC5916240 (PubMed Central)
  57. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Dronamraju R, Jha DK, Eser U, Adams AT, Dominguez D, Choudhury R, Chiang YC, Rathmell WK, Emanuele MJ, Churchman LS, Strahl BD (2018) Nucleic Acids Res 46(3): 1331-1344
    › Primary publication · 29294086 (PubMed) · PMC5814799 (PubMed Central)
  58. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, Rathmell WK, Dayton PA (2018) Theranostics 8(1): 141-155
    › Primary publication · 29290798 (PubMed) · PMC5743465 (PubMed Central)
  59. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, Cancer Genome Atlas Research Network (2017) Cell 171(4): 950-965.e28
    › Primary publication · 29100075 (PubMed) · PMC5693358 (PubMed Central)
  60. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP (2017) Cell 171(3): 540-556.e25
    › Primary publication · 28988769 (PubMed) · PMC5687509 (PubMed Central)
  61. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network (2017) Cancer Cell 32(2): 185-203.e13
    › Primary publication · 28810144 (PubMed) · PMC5964983 (PubMed Central)
  62. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E (2017) Cancer Res 77(19): 5313-5326
    › Primary publication · 28807937 (PubMed) · PMC5626626 (PubMed Central)
  63. Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. Chang EH, Chong WK, Kasoji SK, Fielding JR, Altun E, Mullin LB, Kim JI, Fine JP, Dayton PA, Rathmell WK (2017) BMC Nephrol 18(1): 266
    › Primary publication · 28793871 (PubMed) · PMC5551034 (PubMed Central)
  64. Renal Medullary Carcinoma: Establishing Standards in Practice. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK (2017) J Oncol Pract 13(7): 414-421
    › Primary publication · 28697319 (PubMed) · PMC5508447 (PubMed Central)
  65. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN (2017) Cell Rep 19(13): 2878-2880
    › Primary publication · 28658632 (PubMed) · PMC6141445 (PubMed Central)
  66. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, Cancer Genome Atlas Research Network (2017) Cell 169(7): 1327-1341.e23
    › Primary publication · 28622513 (PubMed) · PMC5680778 (PubMed Central)
  67. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC (2017) JCI Insight 2(12)
    › Primary publication · 28614802 (PubMed) · PMC5470888 (PubMed Central)
  68. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Weyandt JD, Thompson CB, Giaccia AJ, Rathmell WK (2017) Am Soc Clin Oncol Educ Book : 825-832
    › Primary publication · 28561705 (PubMed) · PMC5954416 (PubMed Central)
  69. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB (2017) Oncoimmunology 6(4): e1305535
    › Primary publication · 28507813 (PubMed) · PMC5414873 (PubMed Central)
  70. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN (2017) Cell Rep 18(11): 2780-2794
    › Primary publication · 28297679 (PubMed) · PMC5493145 (PubMed Central)
  71. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, Cancer Genome Atlas Research Network, Weinstein JN, Zhang J, Akbani R, Levine DA (2017) Cancer Cell 31(3): 411-423
    › Primary publication · 28292439 (PubMed) · PMC5599133 (PubMed Central)
  72. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D (2017) Sci Rep : 43356
    › Primary publication · 28256615 (PubMed) · PMC5335708 (PubMed Central)
  73. Untangling ccRCC prognosis with SLINKY. Reinfeld BI, Rathmell WK (2017) Oncotarget 8(12): 18620-18621
    › Primary publication · 28220033 (PubMed) · PMC5386631 (PubMed Central)
  74. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD (2017) Cancer Cell 31(2): 181-193
    › Primary publication · 28162975 (PubMed) · PMC5643159 (PubMed Central)
  75. Integrated genomic and molecular characterization of cervical cancer. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness &Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health &Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeir ão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine &Public Health, Van Andel Research Institute, Washington University in St Louis (2017) Nature 543(7645): 378-384
    › Primary publication · 28112728 (PubMed) · PMC5354998 (PubMed Central)
  76. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, Johnson DB (2017) J Immunother Cancer : 1
    › Primary publication · 28105368 (PubMed) · PMC5240268 (PubMed Central)
  77. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ (2017) Oncogenesis 6(1): e287
    › Primary publication · 28092369 (PubMed) · PMC5294252 (PubMed Central)
  78. Strategies to overcome therapeutic resistance in renal cell carcinoma. Siska PJ, Beckermann KE, Rathmell WK, Haake SM (2017) Urol Oncol 35(3): 102-110
    › Primary publication · 28089416 (PubMed) · PMC5318278 (PubMed Central)
  79. Integrated genomic characterization of oesophageal carcinoma. Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, Case Western Reserve University, Dana-Farber Cancer Institute, Duke University, Greater Poland Cancer Centre, Harvard Medical School, Institute for Systems Biology, KU Leuven, Mayo Clinic, Memorial Sloan Kettering Cancer Center, National Cancer Institute, Nationwide Children’s Hospital, Stanford University, University of Alabama, University of Michigan, University of North Carolina, University of Pittsburgh, University of Rochester, University of Southern California, University of Texas MD Anderson Cancer Center, University of Washington, Van Andel Research Institute, Vanderbilt University, Washington University, Genome Sequencing Center: Broad Institute, Washington University in St. Louis, Genome Characterization Centers: BC Cancer Agency, Broad Institute, Harvard Medical School, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of North Carolina, University of Southern California Epigenome Center, University of Texas MD Anderson Cancer Center, Van Andel Research Institute, Genome Data Analysis Centers: Broad Institute, Brown University:, Harvard Medical School, Institute for Systems Biology, Memorial Sloan Kettering Cancer Center, University of California Santa Cruz, University of Texas MD Anderson Cancer Center, Biospecimen Core Resource: International Genomics Consortium, Research Institute at Nationwide Children’s Hospital, Tissue Source Sites: Analytic Biologic Services, Asan Medical Center, Asterand Bioscience, Barretos Cancer Hospital, BioreclamationIVT, Botkin Municipal Clinic, Chonnam National University Medical School, Christiana Care Health System, Cureline, Duke University, Emory University, Erasmus University, Indiana University School of Medicine, Institute of Oncology of Moldova, International Genomics Consortium, Invidumed, Israelitisches Krankenhaus Hamburg, Keimyung University School of Medicine, Memorial Sloan Kettering Cancer Center, National Cancer Center Goyang, Ontario Tumour Bank, Peter MacCallum Cancer Centre, Pusan National University Medical School, Ribeirão Preto Medical School, St. Joseph’s Hospital &Medical Center, St. Petersburg Academic University, Tayside Tissue Bank, University of Dundee, University of Kansas Medical Center, University of Michigan, University of North Carolina at Chapel Hill, University of Pittsburgh School of Medicine, University of Texas MD Anderson Cancer Center, Disease Working Group: Duke University, Memorial Sloan Kettering Cancer Center, National Cancer Institute, University of Texas MD Anderson Cancer Center, Yonsei University College of Medicine, Data Coordination Center: CSRA Inc., Project Team: National Institutes of Health (2017) Nature 541(7636): 169-175
    › Primary publication · 28052061 (PubMed) · PMC5651175 (PubMed Central)
  80. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Haake SM, Rathmell WK (2017) Cancer 123(2): 200-209
    › Primary publication · 27861752 (PubMed) · PMC5222778 (PubMed Central)
  81. A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound. Kasoji SK, Chang EH, Mullin LB, Chong WK, Rathmell WK, Dayton PA (2017) Ultrason Imaging 39(2): 126-136
    › Primary publication · 27659687 (PubMed) · PMC5599099 (PubMed Central)
  82. Methylated α-tubulin antibodies recognize a new microtubule modification on mitotic microtubules. Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, Rathmell WK, Walker CL (2016) MAbs 8(8): 1590-1597
    › Primary publication · 27594515 (PubMed) · PMC5098444 (PubMed Central)
  83. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK (2016) Cancer Immunol Res 4(10): 820-822
    › Primary publication · 27538576 (PubMed) · PMC5050137 (PubMed Central)
  84. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, Rathmell WK (2016) J Biol Chem 291(40): 21283-21295
    › Primary publication · 27528607 (PubMed) · PMC5076534 (PubMed Central)
  85. Dual Chromatin and Cytoskeletal Remodeling by SETD2. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL (2016) Cell 166(4): 950-962
    › Primary publication · 27518565 (PubMed) · PMC5101839 (PubMed Central)
  86. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Haake SM, Weyandt JD, Rathmell WK (2016) Mol Cancer Res 14(7): 589-98
    › Primary publication · 27330105 (PubMed) · PMC4955752 (PubMed Central)
  87. A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma. Fahey CC, Rathmell WK (2015) Mol Cell Oncol 2(2): e979686
    › Primary publication · 27308442 (PubMed) · PMC4904899 (PubMed Central)
  88. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB (2016) Clin Cancer Res 22(22): 5605-5616
    › Primary publication · 27220961 (PubMed) · PMC5122466 (PubMed Central)
  89. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G, Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M (2016) Nat Genet 48(6): 607-16
    › Primary publication · 27158780 (PubMed) · PMC4884143 (PubMed Central)
  90. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Chism DD, Rathmell WK (2016) Nat Rev Nephrol 12(6): 317-8
    › Primary publication · 27108841 (PubMed) · PMC4871728 (PubMed Central)
  91. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, Richards KL, Locasale JW, Rathmell JC (2016) Cell Metab 23(4): 649-62
    › Primary publication · 27076078 (PubMed) · PMC4832577 (PubMed Central)
  92. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG (2016) Cell 164(3): 550-63
    › Primary publication · 26824661 (PubMed) · PMC4754110 (PubMed Central)
  93. Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK (2016) Clin Cancer Res 22(12): 2950-9
    › Primary publication · 26787754 (PubMed) · PMC4911278 (PubMed Central)
  94. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M (2016) Urol Oncol 34(3): 122.e1-7
    › Primary publication · 26546482 (PubMed) · PMC4761468 (PubMed Central)
  95. The Molecular Taxonomy of Primary Prostate Cancer. Cancer Genome Atlas Research Network (2015) Cell 163(4): 1011-25
    › Primary publication · 26544944 (PubMed) · PMC4695400 (PubMed Central)
  96. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) N Engl J Med 374(2): 135-45
    › Primary publication · 26536169 (PubMed) · PMC4775252 (PubMed Central)
  97. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool. Chang EH, Chong WK, Kasoji SK, Dayton PA, Rathmell WK (2016) Urology : 1-10
    › Primary publication · 26483268 (PubMed) · PMC5500195 (PubMed Central)
  98. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, TCGA Research Network, Perou CM (2015) Cell 163(2): 506-19
    › Primary publication · 26451490 (PubMed) · PMC4603750 (PubMed Central)
  99. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI (2015) Urol Oncol 33(9): 386.e1-6
    › Primary publication · 26122712 (PubMed) · PMC5084688 (PubMed Central)
  100. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z (2015) Carcinogenesis : S254-96
    › Primary publication · 26106142 (PubMed) · PMC4480130 (PubMed Central)
  101. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N (2015) Carcinogenesis : S184-202
    › Primary publication · 26106137 (PubMed) · PMC4492067 (PubMed Central)
  102. Genomic Classification of Cutaneous Melanoma. Cancer Genome Atlas Network (2015) Cell 161(7): 1681-96
    › Primary publication · 26091043 (PubMed) · PMC4580370 (PubMed Central)
  103. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) N Engl J Med 372(26): 2481-98
    › Primary publication · 26061751 (PubMed) · PMC4530011 (PubMed Central)
  104. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. Rathmell KW, Chen F, Creighton CJ (2015) Oncoscience 2(2): 81-90
    › Primary publication · 25859550 (PubMed) · PMC4381700 (PubMed Central)
  105. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snavely A, Rogers AB, Montgomery SA, Rathmell WK, McRee AJ (2015) Gastrointest Cancer : 61-71
    › Primary publication · 25844041 (PubMed) · PMC4383253 (PubMed Central)
  106. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Cancer Genome Atlas Network (2015) Nature 517(7536): 576-82
    › Primary publication · 25631445 (PubMed) · PMC4311405 (PubMed Central)
  107. Ror2 as a therapeutic target in cancer. Debebe Z, Rathmell WK (2015) Pharmacol Ther : 143-8
    › Primary publication · 25614331 (PubMed)
  108. Broad targeting of angiogenesis for cancer prevention and therapy. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD (2015) Semin Cancer Biol : S224-S243
    › Primary publication · 25600295 (PubMed) · PMC4737670 (PubMed Central)
  109. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK (2014) PLoS One 9(12): e116101
    › Primary publication · 25542006 (PubMed) · PMC4277431 (PubMed Central)
  110. Genomic investigation of etiologic heterogeneity: methodologic challenges. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ (2014) BMC Med Res Methodol : 138
    › Primary publication · 25532962 (PubMed) · PMC4292824 (PubMed Central)
  111. Integrated genomic characterization of papillary thyroid carcinoma. Cancer Genome Atlas Research Network (2014) Cell 159(3): 676-90
    › Primary publication · 25417114 (PubMed) · PMC4243044 (PubMed Central)
  112. Renal cell carcinoma. Jonasch E, Gao J, Rathmell WK (2014) BMJ : g4797
    › Primary publication · 25385470 (PubMed) · PMC4707715 (PubMed Central)
  113. Characterization of HPV and host genome interactions in primary head and neck cancers. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, Cancer Genome Atlas Network (2014) Proc Natl Acad Sci U S A 111(43): 15544-9
    › Primary publication · 25313082 (PubMed) · PMC4217452 (PubMed Central)
  114. The somatic genomic landscape of chromophobe renal cell carcinoma. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ (2014) Cancer Cell 26(3): 319-330
    › Primary publication · 25155756 (PubMed) · PMC4160352 (PubMed Central)
  115. Comprehensive molecular profiling of lung adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 511(7511): 543-50
    › Primary publication · 25079552 (PubMed) · PMC4231481 (PubMed Central)
  116. Comprehensive molecular characterization of gastric adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 513(7517): 202-9
    › Primary publication · 25079317 (PubMed) · PMC4170219 (PubMed Central)
  117. PET/CT with (124)I-cG250: great potential and some open questions. Khandani AH, Rathmell WK, Wallen EM, Ivanovic M (2014) AJR Am J Roentgenol 203(2): 261-2
    › Primary publication · 25055257 (PubMed)
  118. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. Rathmell WK, Brooks SA, Parker JS, Nielsen ME (2014) Eur Urol 66(5): e92
    › Primary publication · 25037640 (PubMed) · PMC4294998 (PubMed Central)
  119. HIF1α and HIF2α exert distinct nutrient preferences in renal cells. Arreola A, Cowey CL, Coloff JL, Rathmell JC, Rathmell WK (2014) PLoS One 9(5): e98705
    › Primary publication · 24879016 (PubMed) · PMC4039535 (PubMed Central)
  120. Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Chism DD, Rathmell WK (2014) Clin Cancer Res 20(7): 1721-3
    › Primary publication · 24634386 (PubMed) · PMC4077661 (PubMed Central)
  121. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK (2014) Eur Urol 66(1): 77-84
    › Primary publication · 24613583 (PubMed) · PMC4058355 (PubMed Central)
  122. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B (2014) Oncologist 19(2): 186-92
    › Primary publication · 24449096 (PubMed) · PMC3926786 (PubMed Central)
  123. Racial difference in histologic subtype of renal cell carcinoma. Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK (2013) Cancer Med 2(5): 744-9
    › Primary publication · 24403240 (PubMed) · PMC3892806 (PubMed Central)
  124. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ (2014) Genome Res 24(2): 241-50
    › Primary publication · 24158655 (PubMed) · PMC3912414 (PubMed Central)
  125. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM (2013) Cancer Med 2(4): 545-52
    › Primary publication · 24156027 (PubMed) · PMC3799289 (PubMed Central)
  126. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. Desimone MC, Rathmell WK, Threadgill DW (2013) J Natl Cancer Inst 105(18): 1355-64
    › Primary publication · 23990666 (PubMed) · PMC3776265 (PubMed Central)
  127. The molecular biology of renal cell carcinoma. Keefe SM, Nathanson KL, Rathmell WK (2013) Semin Oncol 40(4): 421-8
    › Primary publication · 23972705 (PubMed)
  128. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK (2013) J Biol Chem 288(36): 26301-10
    › Primary publication · 23893409 (PubMed) · PMC3764835 (PubMed Central)
  129. Ethical challenges: managing oncology drug shortages. Valgus J, Singer EA, Berry SR, Rathmell WK (2013) J Oncol Pract 9(2): e21-3
    › Primary publication · 23814521 (PubMed) · PMC3595447 (PubMed Central)
  130. Physician and stakeholder perceptions of conflict of interest policies in oncology. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK (2013) J Clin Oncol 31(13): 1677-82
    › Primary publication · 23530092 (PubMed) · PMC4525129 (PubMed Central)
  131. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) Cell Metab 17(3): 372-85
    › Primary publication · 23473032 (PubMed) · PMC4003458 (PubMed Central)
  132. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI (2014) Urol Oncol 32(1): 32.e1-9
    › Primary publication · 23434424 (PubMed) · PMC4058502 (PubMed Central)
  133. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J (2013) Lancet Oncol 14(2): 159-167
    › Primary publication · 23333114 (PubMed) · PMC4674067 (PubMed Central)
  134. Kidney cancer. Linehan WM, Rathmell WK (2012) Urol Oncol 30(6): 948-51
    › Primary publication · 23218074 (PubMed) · PMC4419144 (PubMed Central)
  135. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE (2012) BJU Int 110(11 Pt B): E721-6
    › Primary publication · 23016517 (PubMed)
  136. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK (2012) Nucl Med Commun 33(9): 967-73
    › Primary publication · 22714005 (PubMed)
  137. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Khandani AH, Rathmell WK (2012) Semin Nucl Med 42(4): 221-30
    › Primary publication · 22681671 (PubMed)
  138. State of the science: an update on renal cell carcinoma. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK (2012) Mol Cancer Res 10(7): 859-80
    › Primary publication · 22638109 (PubMed) · PMC3399969 (PubMed Central)
  139. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y (2012) Mol Cell 45(2): 233-43
    › Primary publication · 22284679 (PubMed) · PMC3982234 (PubMed Central)
  140. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK (2012) Eur Urol 61(2): 258-68
    › Primary publication · 22030119 (PubMed) · PMC3244546 (PubMed Central)
  141. Carcinoma in a cadaveric transplant kidney. Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC (2012) Urology 79(4): 758-60
    › Primary publication · 22014593 (PubMed)
  142. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK (2011) Mol Oncol 5(5): 465-74
    › Primary publication · 21764651 (PubMed) · PMC3194764 (PubMed Central)
  143. Basic research in kidney cancer. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A (2011) Eur Urol 60(4): 622-33
    › Primary publication · 21741760 (PubMed) · PMC4877128 (PubMed Central)
  144. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Rasmussen N, Rathmell WK (2011) Curr Clin Pharmacol 6(3): 199-206
    › Primary publication · 21470103 (PubMed)
  145. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ (2013) Urol Oncol 31(1): 82-6
    › Primary publication · 21396844 (PubMed)
  146. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK (2010) Genes Cancer 1(2): 152-163
    › Primary publication · 20871783 (PubMed) · PMC2943630 (PubMed Central)
  147. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Cowey CL, Rathmell WK (2008) Expert Opin Drug Discov 3(3): 311-327
    › Primary publication · 20648240 (PubMed) · PMC2906134 (PubMed Central)
  148. Emerging molecular classification in renal cell carcinoma: implications for drug development. Hacker KE, Rathmell WK (2010) Target Oncol 5(2): 75-84
    › Primary publication · 20645016 (PubMed) · PMC3392717 (PubMed Central)
  149. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML (2009) Head Neck Pathol 3(4): 276-82
    › Primary publication · 20596845 (PubMed) · PMC2811562 (PubMed Central)
  150. Renal cell carcinoma: where will the state-of-the-art lead us? Brannon AR, Rathmell WK (2010) Curr Oncol Rep 12(3): 193-201
    › Primary publication · 20425079 (PubMed) · PMC2906141 (PubMed Central)
  151. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV (2010) BMC Syst Biol : 51
    › Primary publication · 20420713 (PubMed) · PMC2876063 (PubMed Central)
  152. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK (2010) Angiogenesis 13(1): 59-69
    › Primary publication · 20221685 (PubMed) · PMC2872996 (PubMed Central)
  153. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. Wright TM, Rathmell WK (2010) J Biol Chem 285(17): 12916-24
    › Primary publication · 20185829 (PubMed) · PMC2857057 (PubMed Central)
  154. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) J Clin Oncol 28(9): 1502-7
    › Primary publication · 20159822 (PubMed) · PMC4525128 (PubMed Central)
  155. Recent updates in renal cell carcinoma. Rathmell WK, Godley PA (2010) Curr Opin Oncol 22(3): 250-6
    › Primary publication · 20154618 (PubMed) · PMC2906148 (PubMed Central)
  156. Neoadjuvant treatment of renal cell carcinoma. Rathmell WK, Pruthi R, Wallen E (2010) Urol Oncol 28(1): 69-73
    › Primary publication · 20123351 (PubMed)
  157. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W (2010) BJU Int 106(3): 349-54
    › Primary publication · 20089114 (PubMed)
  158. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA (2011) Urol Oncol 29(6): 608-13
    › Primary publication · 20022268 (PubMed)
  159. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Cowey CL, Fielding JR, Rathmell WK (2010) Urology 75(5): 1108-13.e1
    › Primary publication · 19931124 (PubMed)
  160. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen EM, Pruthi RS (2011) Urol Oncol 29(4): 378-82
    › Primary publication · 19576797 (PubMed)
  161. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK (2009) Oncogene 28(27): 2513-23
    › Primary publication · 19448672 (PubMed) · PMC2771692 (PubMed Central)
  162. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK (2009) Oncogene 28(14): 1694-705
    › Primary publication · 19252526 (PubMed) · PMC2667565 (PubMed Central)
  163. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Cowey CL, Rathmell WK (2009) Curr Oncol Rep 11(2): 94-101
    › Primary publication · 19216840 (PubMed) · PMC2873025 (PubMed Central)
  164. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) Cancer Cell 14(6): 435-46
    › Primary publication · 19061835 (PubMed) · PMC2621440 (PubMed Central)
  165. VHL type 2B mutations retain VBC complex form and function. Hacker KE, Lee CM, Rathmell WK (2008) PLoS One 3(11): e3801
    › Primary publication · 19030229 (PubMed) · PMC2583047 (PubMed Central)
  166. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK (2008) Urology 72(4): 864-8
    › Primary publication · 18684493 (PubMed)
  167. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Rathmell WK, Monk JP (2008) Urology 72(3): 659-63
    › Primary publication · 18649931 (PubMed)
  168. Renal cell carcinoma. Rini BI, Rathmell WK, Godley P (2008) Curr Opin Oncol 20(3): 300-6
    › Primary publication · 18391630 (PubMed)
  169. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Rathmell WK, Chen S (2008) Expert Rev Anticancer Ther 8(1): 63-73
    › Primary publication · 18095884 (PubMed) · PMC2873028 (PubMed Central)
  170. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC (2007) J Clin Invest 117(12): 3879-89
    › Primary publication · 17992257 (PubMed) · PMC2066197 (PubMed Central)
  171. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ (2007) J Clin Oncol 25(22): 3288-95
    › Primary publication · 17664476 (PubMed)
  172. Renal cell carcinoma. Rathmell WK, Martz CA, Rini BI (2007) Curr Opin Oncol 19(3): 234-40
    › Primary publication · 17414642 (PubMed)
  173. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Rini BI, Rathmell WK (2007) Clin Cancer Res 13(2 Pt 2): 741s-746s
    › Primary publication · 17255303 (PubMed)
  174. Renal cell carcinoma. Rini BI, Campbell SC, Rathmell WK (2006) Curr Opin Oncol 18(3): 289-96
    › Primary publication · 16552243 (PubMed)
  175. Molecularly targeted therapy in renal cell carcinoma. Rathmell WK, Wright TM, Rini BI (2005) Expert Rev Anticancer Ther 5(6): 1031-40
    › Primary publication · 16336094 (PubMed)
  176. VHL: oxygen sensing and vasculogenesis. Rathmell WK, Simon MC (2005) J Thromb Haemost 3(12): 2627-32
    › Primary publication · 15975138 (PubMed)
  177. Renal cell carcinoma. Rathmell WK, Godley PA, Rini BI (2005) Curr Opin Oncol 17(3): 261-7
    › Primary publication · 15818172 (PubMed)
  178. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC (2004) Cancer Res 64(23): 8595-603
    › Primary publication · 15574766 (PubMed)
  179. Renal cell carcinoma. Rathmell WK, Godley PA (2004) Curr Opin Oncol 16(3): 247-52
    › Primary publication · 15069321 (PubMed)
  180. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ (2004) Am J Clin Oncol 27(2): 109-12
    › Primary publication · 15057147 (PubMed)
  181. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Rathmell WK, Acs G, Simon MC, Vaughn DJ (2004) Anticancer Res 24(1): 167-9
    › Primary publication · 15015593 (PubMed)
  182. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC (2003) Cancer Cell 3(1): 75-88
    › Primary publication · 12559177 (PubMed) · PMC4120823 (PubMed Central)
  183. The wheat-grain proteome as a basis for more efficient cultivar identification. Skylas DJ, Copeland L, Rathmell WG, Wrigley CW (2001) Proteomics 1(12): 1542-6
    › Primary publication · 11747214 (PubMed)
  184. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. Rathmell WK, Arguin P, Chan S, Yu A (1999) West J Med 170(2): 110-2
    › Primary publication · 10063398 (PubMed) · PMC1305451 (PubMed Central)
  185. Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination. Smider V, Rathmell WK, Brown G, Lewis S, Chu G (1998) Mol Cell Biol 18(11): 6853-8
    › Primary publication · 9774698 (PubMed) · PMC109268 (PubMed Central)
  186. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Rathmell WK, Kaufmann WK, Hurt JC, Byrd LL, Chu G (1997) Cancer Res 57(1): 68-74
    › Primary publication · 8988043 (PubMed)
  187. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Errami A, Smider V, Rathmell WK, He DM, Hendrickson EA, Zdzienicka MZ, Chu G (1996) Mol Cell Biol 16(4): 1519-26
    › Primary publication · 8657125 (PubMed) · PMC231136 (PubMed Central)
  188. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Rathmell WK, Chu G (1994) Proc Natl Acad Sci U S A 91(16): 7623-7
    › Primary publication · 8052631 (PubMed) · PMC44454 (PubMed Central)
  189. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Smider V, Rathmell WK, Lieber MR, Chu G (1994) Science 266(5183): 288-91
    › Primary publication · 7939667 (PubMed)
  190. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Rathmell WK, Chu G (1994) Mol Cell Biol 14(7): 4741-8
    › Primary publication · 7516471 (PubMed) · PMC358847 (PubMed Central)
  191. Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. Wiens DJ, Mann TK, Fedderson DE, Rathmell WK, Franck BH (1992) Differentiation 51(2): 105-12
    › Primary publication · 1473624 (PubMed)